Keswani Sanjay Chandru 4

What Happened
Sanjay Chandru Keswani, Chief Medical Officer of Neurocrine Biosciences (NBIX), had 3,212 restricted stock units (RSUs) vest on June 2, 2026. The RSUs converted into 3,212 shares (reported as derivative exercise/ conversion). To cover tax withholding obligations, the company withheld 1,733 of those shares at an indicated price of $154.84 per share (tax value ≈ $268,338). No open-market sale occurred; net shares delivered to Keswani were 1,479 (3,212 vested − 1,733 withheld).

Key Details

• Transaction date: June 2, 2026; Form 4 filed June 4, 2026 (timely).
• Vesting/conversion: 3,212 RSUs → 3,212 shares (transaction code M reported at $0.00 acquisition cost).
• Tax withholding: 1,733 shares withheld (transaction code F) at $154.84/share; total tax withholding value ≈ $268,338. No shares were sold on the market.
• Net shares delivered to insider: 1,479 shares.
• Shares owned after transaction: not stated in the filing.
• Relevant footnotes: RSUs were granted June 2, 2025; vesting schedule: 3,212 shares vested 6/2/2026, future vesting of 3,212 (6/2/2027), 3,211 (6/2/2028) and 3,211 (6/2/2029).

Context

• These entries reflect routine vesting of an RSU award and company withholding to satisfy tax obligations, not an open‑market sale or purchase.
• The derivative coding (M) here denotes conversion/settlement of RSUs into shares; the F code denotes shares withheld for taxes.
• Such vesting transactions are common executive compensation events and do not by themselves indicate insider buying or selling intent.